Brought to you by 
Fera buys seven ophthalmic ANDAs from Fougera
24 May 2022
Executive Summary
Through its first deal, Fera Pharmaceuticals (in-licenses or acquires drug candidates for which ANDAs have been filed) has purchased seven ANDAs for prescription sterile anti-infective ophthalmic ointment from Nycomed US's Fougera (topical drugs).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Topical Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fera buys seven ophthalmic ANDAs from Fougera
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice